Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.38 |
| ▸ | GRM6 | O15303 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GSR | P00390 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16200626 | 0.89 | KMT2A (0.45) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL711607 | 0.88 | ALOX15 (0.60) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL7451576 | 0.85 | ALOX15 (0.47) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL7176759 | 0.84 | ALOX15 (0.56) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL8610972 | 0.83 | ALOX15 (0.59) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL28809039 | 0.82 | ALOX15 (0.48) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL1577692 | 0.82 | ALOX15 (0.58) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL22502695 | 0.82 | GRM8 (0.60) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL1373976 | 0.82 | SLC1A1 (0.38) | ALOX15BLMPMP22KMT2AGRM8 | |
| SCHEMBL5496875 | 0.82 | GRM8 (0.60) | ALOX15BLMPMP22KMT2ADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 447 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240138433-A1 | PLANT-BASED INTRAMUSCULAR FAT SUBSTITUTES | BUNGE SA (CH) | 2024-05-02 | — | — | US | claimed |
| EP-4294198-A1 | PLANT-BASED INTRAMUSCULAR FAT SUBSTITUTES | Bunge SA (CH) | 2023-12-27 | — | — | EP | claimed |
| CN-117156975-A | Plant-based intramuscular fat substitutes | 邦吉SA公司 | 2023-12-01 | — | — | CN | claimed |
| WO-2022177943-A1 | PLANT-BASED INTRAMUSCULAR FAT SUBSTITUTES | BUNGE NORTH AMERICA, INC. (US) | 2022-08-25 | — | — | WO | claimed |
| EP-3570875-B1 | PEPTIDE MODULATORS OF THE INTERACTION BETWEEN HUMAN C-PEPTIDE AND HUMAN ELASTIN RECEPTOR FOR THERAPEUTIC USE | BIOTEMPT BV (NL) | 2022-07-06 | — | — | EP | claimed |
| CN-111164238-B | Device for reversible photoelectrochemical water splitting using a bacteriorhodopsin-sensitized photoelectrode | 质子新能源未来公司 | 2022-04-19 | — | — | CN | claimed |
| EP-3390440-B1 | C-TERMINAL LYSINE CONJUGATED IMMUNOGLOBULINS | EISAI R&D MAN CO LTD (JP) | 2022-02-02 | — | — | EP | claimed |
| EP-3694536-A2 | A CELL-BASED SEEDING ASSAY FOR HUNTINGTIN AGGREGATION | The Regents of The University of California (US) | 2020-08-19 | — | — | EP | claimed |
| US-20200255487-A1 | A Cell-Based Seeding Assay for Huntingtin Aggregation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-08-13 | — | — | US | claimed |
| EP-3465221-B1 | BIOANALYTICAL METHOD FOR THE CHARACTERIZATION OF SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | HOFFMANN LA ROCHE (CH) | 2020-07-22 | — | — | EP | claimed |
| JP-3822231-B2 | — | — | 2006-09-13 | — | — | JP | claimed |
| EP-0662122-B1 | IMPROVED ENZYMES FOR THE PRODUCTION OF 2-KETO-L-GULONIC ACID | UNIV RUTGERS (US) | 2004-06-09 | — | — | EP | claimed |
| US-20020045231-A1 | Catalytic antibodies which hydrolyze primary amides and methods for eliciting such antibodies | WELLSTAT BIOCATALYSIS, LLC | 2002-04-18 | — | — | US | claimed |
| EP-0807691-B1 | A method for screening for the presence of a genetic defect associated with thrombosis and/or poor anticoagulant response to activated protein C. | UNIV LEIDEN (NL) | 2001-10-10 | — | — | EP | claimed |
| EP-0696318-A4 | CATALYTIC ANTIBODIES WHICH HYDROLYZE PRIMARY AMIDES AND METHODS FOR ELICITING SUCH ANTIBODIES | IGEN INC (US) | 1998-04-15 | — | — | EP | claimed |
| EP-0696318-A1 | CATALYTIC ANTIBODIES WHICH HYDROLYZE PRIMARY AMIDES AND METHODS FOR ELICITING SUCH ANTIBODIES | IGEN, INC. (a California corporation) (US) | 1996-02-14 | — | — | EP | claimed |
| WO-1994025573-A1 | CATALYTIC ANTIBODIES WHICH HYDROLYZE PRIMARY AMIDES AND METHODS FOR ELICITING SUCH ANTIBODIES | IGEN, INC. (US) | 1994-11-10 | — | — | WO | claimed |
| CN-1093701-A | Antiretroviral hydrazine derivative | CIBA GEIGY AG (CH) | 1994-10-19 | — | — | CN | claimed |
| EP-0359338-B1 | Peptide compounds | HAFSLUND NYCOMED AS (NO) | 1994-08-31 | — | — | EP | claimed |
| US-4642118-A | Man-made skin composed of two layers: collagen and a poly-alpha-amino acid | KOKEN CO., LTD. (JP) | 1987-02-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045231-A1 | Catalytic antibodies which hydrolyze primary amides and methods for eliciting such antibodies | AMY1A, AMY2A, HRH2 | ALOX15 409/4885BLM 2206/4885PMP22 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.